Abstract 576P
Background
As third-generation EGFR tyrosine kinase inhibitors (TKIs) have become the frontline treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC), heterogenous responses are commonly observed. This study aimed to investigate the influence of clonal architecture involving EGFR and co-occurring genetic mutations on the response to EGFR-TKIs.
Methods
We gathered a large, homogenous cohort of treatment-naive patients with advanced EGFR-mutant NSCLC who underwent tissue next-generation sequencing (NGS) and received first-line treatment with third-generation EGFR-TKI. Variant allele frequency (VAF) from NGS was normalized based on copy numbers of genes. The VAF of each mutation relative to the maximum VAF in each sample was computed to determine clonality.
Results
A total of 160 eligible patients were enrolled at SYSUCC from January 2019 to January 2023. The aberrant TP53 gene was the most frequent co-alteration, accounting for 68.1% of total cases. EGFR (51.9%) was the most common gene occupying the maximum VAF, followed by TP53 (28.8%), RBM10 (4.4%), RB1 (1.9%), and PIK3CA (1.3%). Both EGFR and TP53 mutations exhibited potential as dominant or subordinate clones in advanced NSCLC. Notably, EGFR-mutant patients receiving first-line third-generation EGFR-TKIs demonstrated significantly prolonged progress-free survival (PFS) when EGFR dominance clone prevailed over EGFR sub-clonal status (median PFS: 22.0m VS. 15.0m, P=0.008). Conversely, TP53 dominance clone correlated with diminished treatment outcomes compared to TP53 sub-clonal cases (median PFS: 15.1m VS. 17.7m, P=0.05). Multivariate analysis confirmed EGFR clonality and TP53 clonality as independent predictors of EGFR-TKI response. Moreover, the clinical impact of EGFR and TP53 clonality was validated in an independent cohort.
Conclusions
Our proof-of-concept study illuminates the clinical significance of both EGFR and TP53 clonality in EGFR-mutant patients with advanced NSCLC who received first-line third-generation EGFR-TKIs. EGFR or TP53 mutations exhibit potential as dominant or subordinate clones, intricately linked to the efficacy of third-generation EGFR-TKIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract